Molecular Dynamics Target Patents: Leaders, Trends & Gaps 2026
Molecular Dynamics for Target Assessment: Patents Mapping Simulation-Driven Drug Discovery
Filings jumped 240% from 2021 to 2024 (5 to 17 records) the sharpest sustained rise in the trend, concentrated around enhanced sampling and machine-learning-assisted structure prediction. Filings rose from a single record in 2017 to a peak of 27 in 2022, before settling into the 2021-2024 window used for the +240% growth figure. 2025 and 2026 figures are still filling in as later publications catch up with their filing dates.
- 1NANJING UNIV8
- 2IAMBIC THERAPEUTICS INC7
- 3KUANO LTD7
- 4INVITAE CORP6
- 5CITY OF HOPE5
See the full molecular dynamics for target assessment analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who are the leading patent holders in molecular dynamics for target assessment?
No single organisation dominates this field: the top-ranked assignee holds 8 of the 113 records in scope, and the top 5 combined account for only 29.2% of all records. The top 10 assignees together reach 46.9%, meaning more than half of the corpus is held by the remaining long tail of the 78 ranked assignees. This fragmentation reflects a field where academic groups, hardware vendors and drug-discovery software firms all file in relatively small numbers rather than one incumbent building a dominant portfolio.
How fast is patent filing growing in this space?
Filings rose sharply from 5 records in 2021 to 17 in 2024, a 240% increase over that three-year span, with a peak of 27 records in 2022. Filing activity in 2025 and 2026 appears lower in the raw counts, but publication typically lags filing by around 18 months, so those recent years are still incomplete rather than showing an actual decline. The safest complete read on growth ends at 2024.
What technology areas do these patents actually claim?
The largest share of records, 47.8%, carries a bioinformatics classification (IPC G16B), followed by computational chemistry at 23.9% and AI-based computing methods at 20.4%. Medicinal preparations, peptide and protein chemistry, and material analysis and testing classes each appear in a smaller but meaningful share of records. Because many filings carry multiple classifications, most patents in this space combine a simulation or chemistry claim with a data-processing or machine-learning claim rather than isolating one discipline.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Molecular Dynamics for Target Assessment covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.